FDA nominee: CBD shows promise, but many ‘open and unanswered questions’

TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.

 

 

The nominee to take charge of the U.S. Food and Drug Administration (FDA) says he wants to see more research to answer “open and unanswered questions” about CBD.

But he has concerns about CBD products that haven’t undergone pharmaceutical review.Dr. Stephen Hahn, a cancer specialist from Houston who is awaiting Senate confirmation to lead the FDA, is telling U.S. senators that CBD already has “a pathway for medical products.”

“There are some open and unanswered questions that have to be filled in by research,” Hahn told Sen. Jacky Rosen, a Nevada Democrat who asked during the nominee’s confirmation hearing about expediting research on cannabis medical treatments.

Talking specifically about CBD, Hahn said he wants to know:

  • Appropriate dosing.
  • Implications of long-term use.

Hahn pointed out that CBD is approved by the FDA to treat certain types of epilepsy.

“There are also some indications – cancer, palliative-care setting – where CBD might be of benefit,” he said.

We build Industrial Site for Cannabis Oil Extraction. See more at:  PHARMAIUM

 

Contact us:  amg@pharmaium.com

However, Hahn said the FDA has reason to worry about how CBD products are being marketed.

“I think unsubstantiated claims, like we see in the marketplace, are of concern, in terms of things like curing Alzheimer’s or curing cancer.”

The nominee did not say how he would approach the agency’s CBD review, but he concluded that he’s a “huge supporter of getting research and clarity and transparency around the processes to allow us to get the medical products to patients.”

The hemp industry says the FDA’s inaction on allowing over-the-counter CBD use is costing profits and shelf space.

Continue at: https://hempindustrydaily.com/fda-nominee-stephen-hahn-says-cbd-shows-promise-but-many-open-and-unanswered-questions/

The text above is owned by the site above referred.

Here is only a small part of the article, for more please follow the link

Also see:

www.manostaxx.com

 

Manostaxx
Manostaxx – Industrial Management Consulting

Leave a Reply

Your email address will not be published. Required fields are marked *